About the Institute

The La Trobe Institute for Molecular Science (LIMS) is committed to solving global problems and improving the welfare of human societies.

The Institute embodies La Trobe University's strategic vision: to be globally recognised for its excellence, creativity and innovation in relation to the big issues of our time.

Launched in 2009, LIMS brings together the University's leading scientists to create new levels of collaboration, and a multi-disciplinary approach to drive innovation and produce translatable research outcomes.

The LIMS complex has 56 research and support laboratories, advanced research equipment, a 200-seat auditorium, and over 3,000 square metres of teaching facilities. Around 400 La Trobe academics, research fellows, postgraduate students and support staff are based at the Institute. LIMS also has an important regional node: many of its scientists work at La Trobe's Bendigo campus.

The Institute's vision is achieved through excellence in six areas of research strength: cancer, infection and immunity, neurobiology, molecular design, molecular imaging and molecular sensing.

LIMS also has two embedded companies: Hexima, who are developing plant-derived proteins and peptides for application as human therapeutics and the genetic modification of crops; and AdAlta, who are developing the next generation antibody platform, the i-body, to deliver high affinity and specific biologics against a variety of therapeutic and diagnostic targets.

LIMS has outstanding links with the Australian Synchrotron. Several of the Institute's physicists design and build synchrotron components. Game changing research partnerships also enhance the Institute's efforts to raise its research capabilities to new levels of national and international significance. An important collaboration with the Olivia Newton-John Cancer Research Institute facilitates the sharing of knowledge, skills, research, training and facilities.